Literature DB >> 31229353

Towards Immunotherapy for Pediatric Brain Tumors.

Stacie Shiqi Wang1, Pratiti Bandopadhayay2, Misty Rayna Jenkins3.   

Abstract

Pediatric brain tumors are the leading cause of childhood cancer-related death. Immunotherapy is a powerful new approach for treating some refractory cancers; applying this 'fourth pillar' of cancer treatment to pediatric brain tumors is an exciting but challenging prospect. This review offers new perspectives on moving towards successful immunotherapy for pediatric brain tumors, focusing on pediatric high-grade glioma (HGG), a subgroup with universally poor outcomes. We cover chimeric antigen receptor T cell (CAR-T) therapy, vaccine therapy, and checkpoint inhibition in this context, and focus on the need for intimately understanding the growing brain and its immune system. We highlight the challenges associated with the application of immunotherapy in pediatric neuro-oncology, as well as the tissue-specific challenges to be overcome, to achieve improved outcomes.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CAR-T cells; DIPG; DMG; glioblastoma; glioma; immunotherapy; pediatric brain tumor; vaccine; virus

Mesh:

Substances:

Year:  2019        PMID: 31229353     DOI: 10.1016/j.it.2019.05.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  25 in total

1.  Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.

Authors:  Cavan P Bailey; Mary Figueroa; Achintyan Gangadharan; Yanwen Yang; Megan M Romero; Bridget A Kennis; Sridevi Yadavilli; Verlene Henry; Tiara Collier; Michelle Monje; Dean A Lee; Linghua Wang; Javad Nazarian; Vidya Gopalakrishnan; Wafik Zaky; Oren J Becher; Joya Chandra
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

2.  Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.

Authors:  Susan Chi; Kee Kiat Yeo; Chantel Cacciotti; Jungwhan Choi; Sanda Alexandrescu; Mary Ann Zimmerman; Tabitha M Cooney; Christine Chordas; Jessica Clymer
Journal:  J Neurooncol       Date:  2020-07-05       Impact factor: 4.130

Review 3.  T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.

Authors:  Darwin Kwok; Hideho Okada
Journal:  J Neurooncol       Date:  2020-03-17       Impact factor: 4.130

Review 4.  Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.

Authors:  Sebastian Zahnreich; Heinz Schmidberger
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

5.  Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.

Authors:  Flor Mendez; Padma Kadiyala; Felipe J Nunez; Stephen Carney; Fernando M Nunez; Jessica C Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2020-04-24       Impact factor: 12.531

6.  Pediatric primary high-grade spinal glioma: a National Cancer Database analysis of current patterns in treatment and outcomes.

Authors:  Ravi S Nunna; Syed Khalid; Mandana Behbahani; Ankit I Mehta
Journal:  Childs Nerv Syst       Date:  2020-06-12       Impact factor: 1.475

Review 7.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

8.  Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.

Authors:  Li Zhang; Buyi Zhang; Zhangqi Dou; Jiawei Wu; Yasaman Iranmanesh; Biao Jiang; Chongran Sun; Jianmin Zhang
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

Review 9.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

10.  Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.

Authors:  Jason Fangusaro; Maria Giuseppina Cefalo; Maria Luisa Garré; Lynley V Marshall; Maura Massimino; Bouchra Benettaib; Noha Biserna; Jennifer Poon; Jackie Quan; Erin Conlin; John Lewandowski; Mathew Simcock; Neelum Jeste; Darren R Hargrave; François Doz; Katherine E Warren
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.